

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/29317> holds various files of this Leiden University dissertation.

Author: Nes, Johanna Gerarda Hendrica van

Title: Clinical aspects of endocrine therapy of early breast cancer in postmenopausal women

Issue Date: 2014-10-21

12

List of publications
Dankwoord
Curriculum Vitae



List of publications

Journals

- JGH van Nes, LVAM Beex, C Seynaeve, H Putter, A Sramek, S Lardenoye, M Duijm-de Carpentier, I van Rongen, JWR Nortier, HM Zonderland, CJH van de Velde. Minimal impact of adjuvant exemestane or tamoxifen treatment on mammographic breast density in postmenopausal breast cancer patients: a Dutch TEAM trial analysis. *Accepted in Acta Oncologica*
- S Saadatmand, EM de Kruijf, A Sajet, NG Dekker-Ensink, JGH van Nes, H Putter, VTHBM Smit, CJH van de Velde, GJ Liefers, PJK Kuppen. Expression of cell adhesion molecules and prognosis in breast cancer. *Br J Surg*. 2013; 100:252-60
- W van de Water, DBY Fontein, JGH van Nes, JMS Bartlett, ETM Hille, H Putter, T Robson, GJ Liefers, RMH Roumen, C Seynaeve, LY Dirix, R Paridaens, E Meershoek-Klein Kranenbarg, JWR Nortier, CJH van de Velde. Influence of semi-quantitative estrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer – a TEAM study analysis. *Eur J Cancer* 2013; 49:297-304
- AQ van Hoesel, CJH van de Velde, PJK Kuppen, GJ Liefers, H Putter, Y Sato, DA Elashoff, RR Turner, JM Shamonki, EM de Kruijf, JGH van Nes, AE Giuliano, DSB Hoon. Hypomethylation of LINE-1 in primary tumor has poor prognosis in young breast cancer patients: a retrospective cohort study. *Breast Cancer Res Treat*. 2012; 134:1103-14
- JGH van Nes, DBY Fontein, ETM Hille, DW Voskuil, FE van Leeuwen, JCJM de Haes, H Putter, C Seynaeve, JWR Nortier, CJH van de Velde, on behalf of the Dutch TEAM Steering Committee. Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study. *Breast Cancer Res Treat*. 2012; 134:267-76
- EM de Kruijf, A Sajet, JGH van Nes, H Putter, VTHBM Smit, RA Eagle, I Jafferji, J Trowsdale, GJH Liefers, CJH van de Velde, PJK Kuppen. NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study. *BMC Cancer*. 2012; 12:24
- JGH van Nes, EM de Kruijf, H Putter, D Faratian, A Munro, F Campbell, VTHBM Smit, GJ Liefers, PJK Kuppen, CJH van de Velde, JMS Bartlett. Co-expression of SNAI1 and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients. *Breast Cancer Res Treat*. 2012; 133:49-59
- M van Hezewijk, GMC Ranke, JGH van Nes, AM Stiggelbout, GH de Bock, CJH van de Velde. Patients' needs and preferences in routine follow-up for early breast cancer; an evaluation of the changing role of the nurse practitioner. *Eur J Surg Oncol*. 2011;37: 765-73
- AQ van Hoesel, CJH van de Velde, PJK Kuppen, H Putter, EM de Kruijf, JGH van Nes, AE Giuliano, DSB Hoon. Primary tumor classification according to methylation pattern is prognostic in patients with early stage ER-negative breast cancer. *Breast Cancer Res Treat*. 2012; 131:859-69
- P Hadji, L Asmar, JGH van Nes, T Menschik, A Hasenburg, J Kuck, JWR Nortier, CJH van de Velde, SE Jones, M Ziller. The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgian sub-studies. *J Cancer Res Clin Oncol*. 2011;137: 1015-25
- EM de Kruijf, A Sajet, JGH van Nes, R Natanov, H Putter, VTHBM Smit, GJ Liefers, PJ van den Elsen, CJH van de Velde, PJK Kuppen. HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. *J Immunol*. 2010; 185: 7452-9
- JGH van Nes, H Putter, M van Hezewijk, ETM Hille, H Bartelink, L Colette, CJH van de Velde, on behalf of the EORTC Breast Cancer Group. Tailored follow-up for early breast cancer patients: a prognostic index that predicts locoregional recurrence. *Eur J Surg Oncol*. 2010; 36: 617-24
- JGH van Nes, C Seynaeve, S Jones, C Markopoulos, H Putter, CJH van de Velde on behalf of the TEAM Trialists' Group. Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries. *Br J Surg*. 2010; 97: 671-9.
- EM de Kruijf, JGH van Nes, CJH van de Velde, H Putter, VTHBM Smit, GJ Liefers, PJK Kuppen, RAEM Tollenaar, WE Mesker. Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. *Breast Cancer Res Treat*. 2011; 125: 687-96
- JGH van Nes, EM de Kruijf, D Faratian, CJH van de Velde, H Putter, C Falconer, VTHBM Smit, C Kay, MJ van de Vijver, PJK Kuppen, JMS Bartlett. COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients. *Breast Cancer Res Treat*. 2011; 125: 617-85.
- DW Voskuil, JGH van Nes, JMC Junggeburst, CJH van de Velde, FE van Leeuwen, JCJM de Haes. Maintenance of physical activity and body weight in relation to subsequent quality of life in postmenopausal breast cancer patients. *Ann Oncol*. 2010; 21: 2094-101.
- EM de Kruijf, JGH van Nes, A Sajet, QRJC Tummies, H Putter, S Osanto, FM Speetjens, VTHBM Smit, GJ Liefers, CJH van de Velde, PJK Kuppen. The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs cells for chemotherapy in patients with early breast cancer. *Clin Cancer Res*. 2010; 16: 1272-80.
- CJH van de Velde, S Verma, JGH van Nes, C Masterman, KI Pritchard. Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer. *Cancer Treat Rev*. 2010; 36: 54-62.
- JGH van Nes, C Seynaeve, E Maartense, RMH Roumen, RS de Jong, LVAM Beex, WM Meershoek-Klein Kranenbarg, H Putter, JWR Nortier, CJH van de Velde, Cooperating Investigators of the Dutch TEAM trial. Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM)

- trial. *Ann Oncol.* 2010;21: 974-82
- JGH van Nes, VTHBM Smit, H Putter, PJK Kuppen, SJ Kim, M Daitho, J Ding, M Shibayama, S. Numada, K Gohda, T Matsuishi, H Ishihara, S Noguchi, CJH van de Velde. Validation study of the prognostic value of cyclin-dependent kinase (CDK)-based risk in Caucasian breast cancer patients. *Br J Cancer* 2009; 100: 494-500.
 - JGH van Nes, H Putter, JP Julien, M Tubiana-Hulin, M van de Vijver, J Bogaerts, M De Vos, CJH van de Velde, Cooperating Investigators of the EORTC. Pre-operative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC Trial 10902. *Breast Cancer Res Treat.* 2009; 115: 101-3.
 - JSD Mieog, JGH van Nes, CJH van de Velde. De voordelen van pre-operatieve systemische therapie bij borstkanker. *Ned Tijdschr Geneesk.* 2008; 152: 2501-6.
 - A Does-den Heyer, JGH van Nes, AM Stiggelbout, J Bonnema, MAA Caljouw, JWR Nortier, CJH van de Velde. Voorlichting over adjuvante hormonale therapie aan borstkankerpatiënten moet beter. Een rol voor de mammacareverpleegkundige/nurse practitioner. *Ned Tijdschr Oncologie.* 2008.
 - JGH van Nes, CJH van de Velde. The preferred treatment for young women with breast cancer – mastectomy versus breast conservation. *Breast.* 2006; S3-10.
 - JGH van Nes, C Seynaeve, CJH van de Velde, JWR Nortier. Optimale adjuvante hormonale therapie bij postmenopauzale vrouwen met een hormoongevoelig mammacarcinoom Kunnen we door de bomen het bos nog wel zien? *Ned Tijdschr Geneesk.* 2006; 150: 2863-9.
 - JGH van Nes, SC de Jong, A Vissink. Acute sialoadenitis van de glandula parotidea. *Ned Tijdschr Tandheelkd.* 2006; 113: 116-8.
 - JGH van Nes, A Nijssen, A Knuistingh Neven, J Eekhof. Hirsutisme. *Modern Medicine* 2006; 3: 100-2.
 - JGH van Nes, JWR Nortier, CJH van de Velde. Wat leert ons de nieuwe meta-analyse van de EBCICG? Toename van overlevingswinst na langere follow-up. *Ned Tijdschr Geneesk.* 2005; 149: 1978-80.
 - JGH van Nes, CJH van de Velde. Het multidisciplinair mammateam: bevordering van goede zorg. *Ned Tijdschr Geneesk.* 2005; 149: 1929-31.
 - JGH van Nes, JM Hendriks, L Tseng, LC van Dijk, MRHM van Sambeek. Endoscopic aneurysm sac fenestration as a treatment option for growing aneurysms due to type II endoleak or endotension. *J Endovasc Ther* 2005; 12: 430-4.
 - JGH van Nes, SC de Jong. Diagnose in beeld. Acute zwelling in het gelaat. *Ned Tijdschr Geneesk.* 2005; 149: 1716.

Bookchapters

- JGH van Nes, B Lemaire. Hirsutisme. *Kleine kwalen in de Huisartsenpraktijk.* Elsevier Gezondheidszorg. 5^{de} druk, Maarssen 2007. ISBN: 978-90-352-29587; 6^{de} druk, 2013, ISBN: 978-90-352-35595
- JGH van Nes; SC de Jong, MRHM van Sambeek, H van Urk. Paragangliomas of the Head and Neck. *Vascular Surgery: Cases, Questions and Commentaries.* Springer Verlag INC 2nd ed, 2006. ISBN: 1-85233-963-2

Selected presentations

- Quality of life in relation to hormonal treatment of postmenopausal women in the Dutch Tamoxifen Exemestane Adjuvant Multicentre (TEAM) Trial. SABCS Abstract no 21, 2008, San Antonio, Texas, USA
- Tailored follow-up of women with curative treatment for early breast cancer: a prognostic index for local recurrence using data of EORTC-studies. Abstract no 285, ESSO, 2006, Vienna. Awarded with Best Poster Award.
- The preferred treatment for young women – Mastectomy versus breast conservation. *Lecture for the European School of Oncology,* 2005, Londen

Dankwoord

Aan het onderzoek en de totstandkoming van dit proefschrift hebben velen bijgedragen en zonder hen zou dit proefschrift niet zijn geworden tot wat het nu is.

Mijn dank in het bijzonder gaat uit aan alle patiënten die betrokken zijn geweest bij het onderzoek. Tevens speciale dank aan alle medewerkers van het datacentrum.

Tot slot: "Een ieder die het al lang weet, of zou moeten weten, ontzettend bedankt voor de samenwerking en de geweldige tijd waardoor uiteindelijk dit proefschrift tot stand is gekomen!".

Janine

Curriculum Vitae

Johanna Gerarda Hendrica Nes (Janine) was born on April 11, 1977 in Groningen. After graduation from secondary school at the "Openbare Scholengemeenschap Schagen" in 1995, she started her Biomedical Sciences studies in Leiden from where she received her Masters degree in 2004. Scientific internships were performed at the department of Paediatrics of the John Radcliffe Hospital (University of Oxford), at the department of Clinical Genetics of the Leiden University Medical Centre, and at the Forensic Laboratory for DNA Research.

In 1997, she started her medical school studies at Leiden University, and in December 2003 she was qualified as a Medical Doctor. She started as a surgical resident at the Erasmus Medical Centre in Rotterdam in 2004. In 2005, she had the opportunity to start the research for this thesis at the Department of Surgery at the Leiden University Medical Centre (promotores prof. dr. C.J.H. van de Velde and prof. dr. J.W.R. Nortier). Thanks to, among other things, grants of the "Stichting Prof. Michaël-van Vloten Fonds" and the Dutch Foundation "De Drie Lichten", she got the opportunity to work in the Endocrine Cancer Group of the Cancer Research Center of the Western General Hospital in Edinburgh (prof. J.M.S. Bartlett), where she conducted part of her research. In 2008, she worked as a resident at the Department of Surgery in the Kennemer Hospital in Haarlem and later as an occupational health physician.

In 2010, she started her residency programme at the Department of Radiation Oncology of the University Medical Centre Groningen and at the Radiotherapy Institute Friesland in Leeuwarden under supervision of dr. M.A.A.M. Heesters and Ms. A. Slot respectively.

